144 related articles for article (PubMed ID: 37929654)
1. Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
Foucar CE; Foley DH; Aldous J; Burke PW; Pettit KR; Benitez LL; Perissinotti AJ; Marini BL; Boonstra P; Bixby DL
Eur J Haematol; 2024 Mar; 112(3):424-432. PubMed ID: 37929654
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series.
Martynova A; Chiu V; Mert M; Hermel D; Weitz IC
Ann Hematol; 2021 Apr; 100(4):933-939. PubMed ID: 33420879
[TBL] [Abstract][Full Text] [Related]
3. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag in children with severe aplastic anemia.
Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M
Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study.
Fang M; Song H; Zhang J; Li S; Shen D; Tang Y
Pediatr Hematol Oncol; 2021 Oct; 38(7):633-646. PubMed ID: 33724146
[TBL] [Abstract][Full Text] [Related]
6. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.
Imada K; Obara N; Iida H; Imajo K; Maeda T; Usuki K; Fanghong Z; Hombo Y; Tajima T; Kumagai A; Matsuda A; Nakao S
Intern Med; 2021 Apr; 60(8):1159-1168. PubMed ID: 33229810
[TBL] [Abstract][Full Text] [Related]
7. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
Jin Y; Li R; Lin S; Jia J; Yang Y; Zhang D; He G; Li J
Ann Hematol; 2022 Nov; 101(11):2413-2419. PubMed ID: 36028583
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
McQuilten Z; Heritier S; Fox L; Fox V; Young L; Blombery P; Cunningham I; Curnow J; Higgins A; Hiwase DK; Filshie R; Firkin F; Lacaze P; Mason K; Mills AK; Pepperell D; Patil S; Stevenson W; Szer J; Waters N; Wilson K; Ting S; Wood E
BMJ Open; 2024 Jan; 14(1):e076246. PubMed ID: 38238183
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
Peffault de Latour R; Kulasekararaj A; Iacobelli S; Terwel SR; Cook R; Griffin M; Halkes CJM; Recher C; Barraco F; Forcade E; Vallejo JC; Drexler B; Mear JB; Smith AE; Angelucci E; Raymakers RAP; de Groot MR; Daguindau E; Nur E; Barcellini W; Russell NH; Terriou L; Iori AP; La Rocca U; Sureda A; Sánchez-Ortega I; Xicoy B; Jarque I; Cavenagh J; Sicre de Fontbrune F; Marotta S; Munir T; Tjon JML; Tavitian S; Praire A; Clement L; Rabian F; Marano L; Hill A; Palmisani E; Muus P; Cacace F; Frieri C; van Lint MT; Passweg JR; Marsh JCW; Socié G; Mufti GJ; Dufour C; Risitano AM;
N Engl J Med; 2022 Jan; 386(1):11-23. PubMed ID: 34986284
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China].
Yang WR; Han B; Chang H; Wu BY; Meng FK; Ji DX; Li YM; Zheng ZJ; Fei Y; Shen JP; Hu P; Ding XQ; Zhang P; Wang YQ; Zhang FK
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):890-895. PubMed ID: 33333690
[No Abstract] [Full Text] [Related]
11. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?
Huang LF; Li L; Jia JS; Yang Y; Lin SY; Meng FK; Zhang DH; He GS
Transplant Cell Ther; 2022 Sep; 28(9):586.e1-586.e7. PubMed ID: 35609866
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children.
Jie M; Fu L; Li S; He Y; Yao J; Cheng X; Zhang L; Zheng J; Zhang R; Wu R
Pediatr Hematol Oncol; 2021 Oct; 38(7):647-657. PubMed ID: 33798022
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag for the treatment of aplastic anemia: current perspectives.
Lum SH; Grainger JD
Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
[TBL] [Abstract][Full Text] [Related]
16. Recent developments in drug therapy for aplastic anemia.
Willis L; Rexwinkle A; Bryan J; Kadia TM
Ann Pharmacother; 2014 Nov; 48(11):1469-78. PubMed ID: 25184310
[TBL] [Abstract][Full Text] [Related]
17. Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.
Li R; Zhou J; Liu Z; Chen X; Long Q; Yang Y; Lin S; Jia J; He G; Li J
Front Immunol; 2022; 13():884312. PubMed ID: 35720405
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS
Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188
[TBL] [Abstract][Full Text] [Related]
19. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.
Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP
Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252
[TBL] [Abstract][Full Text] [Related]
20. Management of the refractory aplastic anemia patient: what are the options?
Marsh JC; Kulasekararaj AG
Hematology Am Soc Hematol Educ Program; 2013; 2013():87-94. PubMed ID: 24319168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
